These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 21942462)

  • 1. Economic impact of tobramycin in patients with cystic fibrosis in a managed care population.
    Wertz DA; Chang CL; Stephenson JJ; Zhang J; Kuhn RJ
    J Med Econ; 2011; 14(6):759-68. PubMed ID: 21942462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
    Woodward TC; Brown R; Sacco P; Zhang J
    J Med Econ; 2010; 13(3):492-9. PubMed ID: 20670159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
    Gibson RL; Emerson J; Mayer-Hamblett N; Burns JL; McNamara S; Accurso FJ; Konstan MW; Chatfield BA; Retsch-Bogart G; Waltz DA; Acton J; Zeitlin P; Hiatt P; Moss R; Williams J; Ramsey BW
    Pediatr Pulmonol; 2007 Jul; 42(7):610-23. PubMed ID: 17534969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
    Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L
    Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease.
    Murphy TD; Anbar RD; Lester LA; Nasr SZ; Nickerson B; VanDevanter DR; Colin AA
    Pediatr Pulmonol; 2004 Oct; 38(4):314-20. PubMed ID: 15334509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed.
    Boccuzzi SJ; Martin J; Stephenson J; Kreilick C; Fernandes J; Beaulieu J; Hauch O; Kim J
    Curr Med Res Opin; 2009 Dec; 25(12):2853-64. PubMed ID: 19916729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
    Hansen CR; Pressler T; Høiby N
    J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation.
    Schechter MS; Trueman D; Farquharson R; Higuchi K; Daines CL
    Ann Am Thorac Soc; 2015 Jul; 12(7):1030-8. PubMed ID: 26053185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis.
    Hennig S; McKay K; Vidmar S; O'Brien K; Stacey S; Cheney J; Wainwright CE
    J Cyst Fibros; 2014 Jul; 13(4):428-34. PubMed ID: 24565869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.
    Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM
    J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of high resolution computerized tomography (HRCT) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung disease.
    Nasr SZ; Sakmar E; Christodoulou E; Eckhardt BP; Streetman DS; Strouse PJ
    Pediatr Pulmonol; 2010 May; 45(5):440-9. PubMed ID: 20425851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of Tobramycin nebuliser solution in cystic fibrosis.
    Iles R; Legh-Smith J; Drummond M; Prevost A; Vowler S
    J Cyst Fibros; 2003 Sep; 2(3):120-8. PubMed ID: 15463860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland.
    Stelmach I; Korzeniewska A; Stelmach W
    Respiration; 2008; 75(2):178-81. PubMed ID: 17435382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
    Med Lett Drugs Ther; 2013 Jun; 55(1419):51-2. PubMed ID: 23797798
    [No Abstract]   [Full Text] [Related]  

  • 17. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
    Strateva T; Petrova G; Mitov I
    J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Sansgiry SS; Joish VN; Boklage S; Goyal RK; Chopra P; Sethi S
    J Med Econ; 2012; 15(2):219-24. PubMed ID: 22084956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost of home and hospital care for patients with cystic fibrosis followed up in two reference medical centers in France.
    Horvais V; Touzet S; François S; Bourdy S; Bellon G; Colin C; Durieu I
    Int J Technol Assess Health Care; 2006; 22(4):525-31. PubMed ID: 16984688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis.
    Panguluri S; Gunda P; Debonnett L; Hamed K
    Clin Drug Investig; 2017 Aug; 37(8):795-805. PubMed ID: 28643178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.